October 16, 2026, delivered 3 ophthalmic FDA approvals that, taken together, touch nearly every corner of the eye care ...
Docking the trailing haptic is the step where surgeons most often struggle with the Yamane technique, according to Murtaza K.
Omur Ucakhan, MD, explains why artificial tears are not interchangeable and how dry eye phenotype should guide formulation ...
Eleonora Lad, MD, PhD, Dimitra Skondra, MD, PhD, and John Kitchens, MD, point to structure and function, diet and the gut, ...
A study published in JAMA Ophthalmology 1 reported that spectacle lenses with highly aspherical lenslets (HAL) are safe and ...
The milestone moves what Oculis describes as the first genotype-guided registrational trial in DED a step closer to a readout ...
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual ...
Timothy Janetos, MD, explained when to refer uveitis to a specialist and why access to uveitis care remains limited.
LUCIA, the second of 2 pivotal phase 3 trials in neovascular (wet) age-related macular degeneration (AMD), missed its primary ...
How should clinicians recognize Demodex blepharitis, and which specialists should be looking for it? These questions framed a recent Ophthalmology Times Clinical Forum in New Orleans, Louisiana: “ ...
SpyGlass Pharma has reported 4-year interim results from the first-in-human (FIH) trial of its Bimatoprost Drug Pad-IOL System (BIM-IOL System), extending what the company describes as the “longest ...
The FDA has approved Enspryng (satralizumab, Genentech) for thyroid eye disease (TED), making the drug the first subcutaneous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results